ORINF News and Press, Orion Corp New B Shs From 02/27/23

ORION CORPORATION PRESS RELEASE 27 February 2023 at 9:00 EET D arolutamide receives approval for additional prostate cancer indication in Japan Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer ...

ORION CORPORATION PRESS RELEASE 27 January 2023 at 14:00 EET Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer CHMP recommendation is based on the data from the Phase III ARASENS trial, which d...

Orion Oyj ( OTCPK:ORINF ): 1H GAAP EPS of €0.88. Revenue of €553.4M (+5.7% Y/Y). Operating profit was EUR 153 million. Return on capital employed before taxes  was 34%. Cash flow from operating activities per share was EUR 0.59. The out...

Orion Oyj (ORINF) Q2 2022 Results Conference Call July 15, 2022 6:30 AM ET Company Participants Tuukka Hirvonen - Head, IR Timo Lappalainen - CEO Jari Karlson - CFO Conference Call Participants Jo Walton - Credit Suisse Sami Sarkamies - Danske Ban...

The following slide deck was published by Orion Oyj in conjunction with their 2022 Q2 earnings call. For further details see: Orion Oyj 2022 Q2 - Results - Earnings Call Presentation

Orion Oyj (ORINF) Q1 2022 Results Conference Call April 28, 2022 06:30 AM ET Company Participants Tuukka Hirvonen - Head, IR Timo Lappalainen - CEO Jari Karlson - CFO Conference Call Participants Harry Sephton - Credit Suisse Sami Sarkamies - Danske Bank Presentation Tuukka Hirvonen Good afte...

Orion Oyj press release (OTCPK:ORINF): Q1 GAAP EPS of €0.41. Revenue of €270.6M (+0.7% Y/Y). Operating profit was €71M Profit before taxes was €72M Equity ratio was 53%. Return on capital employed before taxes was 36%. Return on equity after tax...

My portfolio crossed the mark where I could lock in capital gains, switch decidedly to income stocks and retire today. That is, if these income stocks yield at least some 4.5%. Yield is easy to find, but can it be relied on? For further details see: High Yield And Low Co...

AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...